help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orskov, L.
Right arrow Articles by Orskov, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orskov, L.
Right arrow Articles by Orskov, H.

Journal of Clinical Endocrinology & Metabolism, Vol 68, 276-282, Copyright © 1989 by Endocrine Society


ARTICLES

Influence of growth hormone on glucose-induced glucose uptake in normal men as assessed by the hyperglycemic clamp technique

L Orskov, O Schmitz, JO Jorgensen, J Arnfred, N Abildgaard, JS Christiansen, KG Alberti and H Orskov
First University Clinic of Internal Medicine, Kommunehospitalet, Aarhus, Denmark.

To determine whether physiological increments in circulating GH concentrations influence glucose-induced glucose uptake (GIGU), two- step sequential hyperglycemic clamp (plasma glucose, 6 and 14 mmol/L) studies were performed in six normal subjects with and without GH infusion (40 ng/kg.min). The latter resulted in serum GH levels of 15 +/- 1 (+/- SE) microgram/L. Infusion of somatostatin (250 micrograms/h during step 1 and 750 micrograms/h during step 2) together with a replacement dose of insulin (1.1 pmol/kg.min) resulted in serum insulin levels comparable to basal levels in both studies. The GIGU ([3- 3H]glucose), assessed as the difference between steps 2 and 1 glucose utilization during the final 60 min of each step (150 min) was markedly impaired during GH infusion (with GH, 1.1 +/- 0.2 mg/kg.min; without GH, 3.1 +/- 0.3 mg/kg.min; P less than 0.001). Moreover, the percent increase in glucose uptake was considerably reduced during hypersomatotropinemia (with GH, 44 +/- 9%; without GH, 97 +/- 11%; P less than 0.01). In the GH infusion as well as control studies, endogenous glucose production (EGP) was similar at the two levels of glycemia, whereas GH infusion approximately doubled EGP [2.3 +/- 0.2 vs. 1.1 +/- 0.3 mg/kg.min and 2.0 +/- 0.4 vs. 1.1 +/- 0.4 mg/kg.min (step 1 and 2, respectively)]. We conclude that moderate hypersomatotropinemia for several hours is characterized by impaired GIGU as well as augmented EGP.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. M. Buijs, J. A. Romijn, J. Burggraaf, M. L. de Kam, M. Frolich, M. T. Ackermans, H. P. Sauerwein, A. F. Cohen, A. E. Meinders, and H. Pijl
Glucose homeostasis in abdominal obesity: hepatic hyperresponsiveness to growth hormone action
Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E63 - E68.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
H. Norrelund, C. Djurhuus, J. O. L. Jorgensen, S. Nielsen, K. S. Nair, O. Schmitz, J. S. Christiansen, and N. Moller
Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients
Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E737 - E743.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. Nielsen, N. Moller, J. S. Christiansen, and J. O.L. Jorgensen
Pharmacological Antilipolysis Restores Insulin Sensitivity During Growth Hormone Exposure
Diabetes, October 1, 2001; 50(10): 2301 - 2308.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
H. E. Botker, H. Wiggers, M. Bottcher, J. S. Christiansen, T. T. Nielsen, A. Gjedde, and O. Schmitz
Short-term effects of growth hormone on myocardial glucose uptake in healthy humans
Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E1053 - E1059.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. M. Piatti, L. D. Monti, A. Caumo, M. Conti, F. Magni, M. Galli-Kienle, E. Fochesato, A. Pizzini, L. Baldi, G. Valsecchi, et al.
Mediation of the Hepatic Effects of Growth Hormone by Its Lipolytic Activity
J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1658 - 1663.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Christopher, F. L. Hew, M. Oakley, C. Rantzau, and F. Alford
Defects of Insulin Action and Skeletal Muscle Glucose Metabolism in Growth Hormone-Deficient Adults Persist after 24 Months of Recombinant Human Growth Hormone Therapy
J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1668 - 1681.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society